NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

NovaBridge Biosciences (NBP) Stock Analysis

NovaBridge Biosciences (NBP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

NBP

$1.80

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NBP with… →

NBP Key Statistics

As of Sep 4, 2026
Trading
Open
$1.79
Previous Close
$1.80
Day's Range
1.77–1.82
52-Week Range
1.46–6.79
Volume
71.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.50
Valuation
Market Cap
$208.17M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.69
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$46.27M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
115.65M
1-Year Return
−58.62%
Dividend and dates
Avg Volume
451.25K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NBP Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−54.77%
2025+368.24%
2024−55.26%
2023−54.55%
2022−91.18%
2021+0.51%
2020+277.20%

As of September 4, 2026.

NBP Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$46.27M—
2024$0.00−$22.23M—
2023$632.00K−$207.73M−32868.5%
2022−$1.55M−$371.05M23923.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$94.27M−$46.27M—
2024$0.00—−$51.43M−$22.23M—
2023$632.00K$3.90M−$48.98M−$207.73M−32868.5%
2022−$1.55M−$36.06M−$53.08M−$371.05M23923.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NBP Valuation vs Biotechnology Median

Median of 656 stocks
MetricNBPBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

NovaBridge Biosciences (NBP) is capitalised at $208.17M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 30 employees.

NBP last closed at $1.80 on September 4, 2026. The close was unchanged from the previous session. Over the past 52 weeks the price has ranged from $1.46 to $6.79. The latest close sits 23.29% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $46.27M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −0.69.

Across the 4 fiscal years on file, revenue moves from −$1.55M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 1.5. Daily returns over the trailing 6 years annualize to a volatility of 91.25%. The trailing one-year price return is −58.62%. Measured over 5 years, that is −52.14% a year compounded.

Growth & Income

No dividend is on file for NBP.

2026 is still running; the price is −54.77% year to date. Across the complete calendar years on file, 2025 returned +368.24% and 2022 returned −91.18%. Of the 6 complete calendar years on file, 3 finished higher.

Peer Comparison

NovaBridge Biosciences (NBP) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
NovaBridge Biosciences NBP $208.17M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. NovaBridge Biosciences has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About NovaBridge Biosciences

NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.

Visit website →